key: cord-0955749-bylbauto
authors: Veyre, Florian; Poulain-Veyre, Corinne; Esparcieux, Aurélie; Monsarrat, Nicolas; Aouifi, Abdellah; Lapeze, Joel; Chatelard, Philippe
title: Femoral arterial thrombosis in a young adult following non-severe COVID-19
date: 2020-07-28
journal: Ann Vasc Surg
DOI: 10.1016/j.avsg.2020.07.013
sha: a67a1ab875fa27e939eb8c90fd27591b10237184
doc_id: 955749
cord_uid: bylbauto

INTRODUCTION: Few cases of arterial thromboembolisms have been reported after 2019 coronavirus disease (COVID-19), in case of severe infection or elderly patients. We report a case of femoral arterial thrombosis in a young patient following non-severe infection. CASE DESCRIPTION: A common femoral artery thrombosis extended in the first third of superficial and profunda femoral arteries associated with tibial posterior and popliteal arteries thrombosis were diagnosed in a 24 year-old man complaining of right lower limb pain for one month. The evolution was good after anticoagulation and antiaggregant treatments and thrombectomy. Etiologic assessment was negative except non-severe COVID-19. DISCUSSION: 2019 coronavirus accesses host cells via angiotensin-converting enzyme 2 protein, abundant in the lung, also expressed by endothelial cells and COVID-19 is associated with important inflammatory syndrome and coagulopathy, leading to vascular lesions. Thrombosis prevalence is not fully established, seems to be higher in case of major inflammation and in intensive care unit (ICU). Arterial thromboembolisms are described in many vascular territories, each time in elderly patients or severe infection. We described a femoral arterial thrombosis in a young patient with negative etiological assessment except non-severe COVID-19. Treatment consists in anticoagulation and antiaggregant drugs and thrombectomy. Preventing venous thromboembolism treatment is recommended in case of severe infection or in ICU but there is no clear recommendation for arterial thromboembolism prevention. This case should lead us to be very careful to arterial event risk even if the infection is non-severe and the patient young.

(2) Médecine Vasculaire, Vienne, France.

(3 patients or severe infection. We described a femoral arterial thrombosis in a young 75 patient with negative etiological assessment except non-severe COVID-19. 76

Treatment consists in anticoagulation and antiaggregant drugs and thrombectomy. 77

Preventing venous thromboembolism treatment is recommended in case of severe 78 infection or in ICU but there is no clear recommendation for arterial thromboembolism 79

prevention. This case should lead us to be very careful to arterial event risk even if 80 the infection is non-severe and the patient young. 1.1%, in Milan Hospital, with higher rate in intensive care unit (ICU) (9) . 156

Thromboembolic risk seems to be higher in severe infections, because of major 157 inflammation and need of ICU (5) . Thus, in Klok et al study, cumulative incidence of a 158 composite outcome of vascular events (acute pulmonary embolism, deep-vein 159 thrombosis, ischemic stroke, myocardial infarction, systemic arterial embolism) was 31%, incidence of venous thromboembolisms was 27% while 3.7% were arterial 161 events, among patients in ICU(10). 162

Arterial complications take various forms. In children, COVID-19 is commonly 163 asymptomatic but Kawasaki-like syndrome are described(11). In adult, arterial 164 thromboembolism have been described. Acute coronary syndrome and myocardial 165 infarction have been reported in case of COVID-19 but seems to be 166 infrequent (5, 9, 12) The treatment of this femoral artery thrombosis was standard, using aspirin, LMWH 177 and thrombectomy. Using drugs to prevent thrombosis in COVID-19 context remains 178 debated. To prevent venous events, prophylactic anticoagulation in high risk 179 situations is essential (5) . Prevention of arterial complications is more difficult. Indeed, 180 some antiviral drugs such as ritonavir interact with certain antithrombotic treatments, 181 making their use complicated (5) . Moreover, determining which patient is high arterial 182 thromboembolism risk seems uneasy, since it could happen on non-pathological 183 arteries, in young patient with non-severe COVID-19, as we have reported here. 

Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A 232 Comprehensive Evaluation of Clinical and Basic Evidence

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl 239

COVID19 coagulopathy in Caucasian patients

COVID-19 243 and Thrombotic or Thromboembolic Disease: Implications for Prevention

Journal of the American College of 245 Cardiology

Antiphospholipid Antibodies in Patients with Covid-19

Acute upper limb 250 ischemia in a patient with COVID-19

Concomitant 253 hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with 254 COVID 19 and acute promyelocytic leukemia

Venous 256 and arterial thromboembolic complications in COVID-19 patients admitted to an 257 academic hospital in

259 et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-260 19

COVID-19 and Kawasaki Disease: Finding the 262 Signal in the Noise

Risk of 264 peripheral arterial thrombosis in COVID-19

Acute aorto iliac and mesenteric arterial 267 thromboses as presenting features of COVID 19

Concomitant acute aortic thrombosis and 270 pulmonary embolism complicating COVID-19 pneumonia. Diagnostic and 271 Interventional Imaging

Acute ischemic stroke 273 complicating common carotid artery thrombosis during a severe COVID-19 infection